Ad Details ID14405197
Listing Date15th August, 2022
Last Updated15th August, 2022
To date, our technology yielded the first candidate for clinical development, a proprietary Cys-tagged single-chain vascular endothelial growth factor (scVEGF) derivatized with a contrast agent for PET imaging of VEGF receptors. These receptors play a pivotal role in tumor angiogenesis and their inhibition is the major goal of anti-angiogenic therapies. We believe that imaging VEGF receptors in tumor vasculature can provide crucial information for early diagnostics, development and monitoring therapeutic regimens, and rational patient selection for complex and very expensive treatments. Currently, there are no contrast agents for imaging VEGF receptors and our lead candidate is being developed to satisfy this unmet need.
SibTech is currently looking for business partnerships and scientific collaboration with industrial and academic groups seeking to expand the use of existing and emerging biopharmaceutical proteins.
LabX Member Since15th August, 2022 (3 months ago)
Ad Details 14405197